IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma

Intensity Modulated Radiotherapy Plus Cisplatin Versus Intensity Modulated Radiotherapy in Patients With Stage 2 Nasopharyngeal Carcinoma: A Phase 3 Multicenter, Open-label, Randomized, Non-inferior Clinical Trial

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03068936

Enrollment

716

Registered

2017-03-03

Start date

2017-03-31

Completion date

2021-09-30

Last updated

2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Keywords

Nasopharyngeal Carcinoma, Intensity modulated radiotherapy, Cisplatin

Brief summary

Nasopharyngeal carcinoma has high incidence in the southern China, especially in Guangdong Province. In the world, the standardized morbidity has reached 30/10 million in men while in women, about 13/10 million. At present, the incidence of nasopharyngeal carcinoma in China accounted for more than 80% of the world. The cancer-related deaths is in the eighth, which is a serious threat to our people's health and life. A recent multi-center phase II study of stage II nasopharyngeal carcinoma showed that: compared with Intensity Modulation Radiotherapy (IMRT) plus cisplatin, the 3 year local control rate, regional control rate, distant metastasis-free survival rate and disease-specific survival rate of IMRT were similar, but the side effects of radiotherapy alone group were lower. Based on the results of the phase II clinical study, the investigators designed this phase III clinical study, with the aim to compared the efficacy and toxicity of these two treatment programs. And finally to provide sufficient evidence for the treatment of stage II nasopharyngeal carcinoma.

Interventions

RADIATIONIntensity modulated radiotherapy

Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)

DRUGCisplatin

Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* The sex of the subject is not limited, the age is from 18 to 70 years old; * Histologically proven nasopharyngeal squamous cell carcinoma, World Health Organization (WHO) II-III type; * Union Internationale Contre le Cancer(UICC) stage 9 clinical stage II patients； * Karnofsky score ≥ 80 points; * No evidence of distant metastasis; * Having an nasopharyngeal MRI before treatment ,which can measure the size of the tumor in order to analyze the effect.

Exclusion criteria

* The subject had previously suffered from other malignancies (except non-melanotic skin cancer or cervical carcinoma in situ); * Previously received immunotherapy; * Previously received chemotherapy; * Previously received radiation therapy; * Patients who had previously undergone surgical treatment for head and neck tumors (excluding cervical lymphadenectomy); * Evidence of distant metastases or other malignancies at the same time.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival rate	up to 3 years	Refers to the time from included to death due to any cause.

Contacts

Primary ContactDehua Wu

18602062748@163.com18602062748

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026